The cost-effectiveness of adding infliximab to usual therapy in the treatment of psoriatic arthritis

被引：0
|
作者：
Marra, CA
Maetzel, A
Farewell, VT
Rashidi, AA
Shi, P
Antoni, C
Wong, JB
Gladman, DD
机构：
[1] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[2] Toronto Gen Res Inst, Toronto, ON, Canada
[3] Inst Publ Hlth, Cambridge, England
[4] Schering Plough Corp, Kenilworth, NJ 07033 USA
[5] Tufts New England Med Ctr, Boston, MA USA
[6] Toronto Western Res Inst, Toronto, ON, Canada
来源：
VALUE IN HEALTH | 2005年 / 8卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)62585-5
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：242 / 242
页数：1
相关论文
共 50 条
  • [1] The cost-effectiveness of adding infliximab to usual therapy in the treatment of psoriatic arthritis
    Marra, CA
    Farewell, V
    Antoni, C
    Rashidi, A
    Maetzel, A
    Kavanaugh, A
    Mease, P
    Wong, JB
    Gladman, DD
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 333 - 333
  • [2] Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis
    Cummins, Ewen
    Asseburg, Christian
    Punekar, Yogesh Suresh
    Shore, Emily
    Morris, James
    Briggs, Andrew
    Fenwick, Elisabeth
    VALUE IN HEALTH, 2011, 14 (01) : 15 - 23
  • [3] The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis
    Vergel, Y. Bravo
    Hawkins, N. S.
    Claxton, K.
    Asseburg, C.
    Palmer, S.
    Woolacott, N.
    Bruce, I. N.
    Sculpher, M. J.
    RHEUMATOLOGY, 2007, 46 (11) : 1729 - 1735
  • [4] A COST-EFFECTIVENESS ANALYSIS OF BIOSIMILAR INFLIXIMAB (INFLECTRAO) FOR THE TREATMENT OF PSORIATIC ARTHRITIS IN NINE EUROPEAN COUNTRIES
    Rencz, F.
    Brodszky, V
    Pentek, M.
    Gulacsi, L.
    Baji, P.
    VALUE IN HEALTH, 2016, 19 (07) : A540 - A541
  • [5] Cost-effectiveness of infliximab in the treatment of rheumatoid arthritis in clinical practice
    Virkki, L. M.
    Konttinen, Y. T.
    Peltomaa, R.
    Suontama, K.
    Saario, R.
    Immonen, K.
    Jantti, J.
    Tuomiranta, T.
    Nykanen, P.
    Hameenkorpi, R.
    Heikkila, S.
    Isomaki, P.
    Nordstrom, D.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2008, 26 (06) : 1059 - 1066
  • [6] Sequential biologic therapy in the treatment of active psoriatic arthritis in China: a cost-effectiveness analysis
    Xie, Ouyang
    Wu, Meiyu
    Li, Andong
    Meng, Kehui
    Xiang, Heng
    Tan, Chongqing
    Peng, Liubao
    Ge, Yan
    Wan, Xiaomin
    CLINICAL RHEUMATOLOGY, 2025, : 1597 - 1606
  • [7] COST-EFFECTIVENESS ANALYSIS OF BIOLOGIC THERAPIES FOR TREATMENT OF PSORIATIC ARTHRITIS
    Gharaibeh, M.
    Folse, H. J.
    Stolshek, B.
    Zou, D.
    Harris, M.
    Collier, D.
    Malone, D. C.
    VALUE IN HEALTH, 2018, 21 : S196 - S197
  • [8] COST-EFFECTIVENESS OF SECUKINUMAB FOR THE TREATMENT OF ACTIVE PSORIATIC ARTHRITIS IN THE UK
    Kirkham, B.
    Buchanan, V
    Sullivan, W.
    Graham, C. N.
    Miles, L.
    Jugl, S. M.
    Gunda, P.
    Halliday, A.
    VALUE IN HEALTH, 2017, 20 (09) : A536 - A536
  • [9] Cost-effectiveness of infliximab for rheumatoid arthritis in Spain
    Wong, JB
    Ballina, J
    Fernandez-Sueiro, J
    Garcia-Vadillo, J
    Gonzalez-Fernandez, C
    Gonzalez-Crespo, M
    Gratacos, J
    Ivorra, J
    Navarro-Sarabia, F
    Tornero, J
    Casado, MA
    Fosbrook, L
    Pocovi, A
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 520 - 521
  • [10] COST-EFFECTIVENESS OF APREMILAST IN PSORIATIC ARTHRITIS IN SCOTLAND
    Mughal, F.
    Cawston, H.
    Cure, S.
    Morris, J.
    Tencer, T.
    Zhang, F.
    VALUE IN HEALTH, 2015, 18 (07) : A644 - A644
12345